|Bid||168.90 x 200|
|Ask||173.30 x 200|
|Day's Range||170.14 - 172.63|
|52 Week Range||133.64 - 184.21|
|PE Ratio (TTM)||16.28|
|Dividend & Yield||4.60 (2.68%)|
|1y Target Est||N/A|
In 2Q17, Amgen’s (AMGN) Aranesp generated revenues of ~$535 million, which represented a 6% year-over-year rise.
In 2Q17, Amgen’s (AMGN) Vectibix generated revenues of ~$168 million, which represented a ~5% YoY (year-over-year) rise and a ~14% QoQ (quarter-over-quarter) rise. In the US, Vectibix generated revenues ...
Biogen (BIIB) has had a good, though not great year. Is it time to add it to your portfolio? Shares of Biogen have gained 11.5% so far this year, and while that's better than the S&P 500's 10.3% rise during ...